4.5 Article

Lycium barbarum polysaccharides protect rat liver from non-alcoholic steatohepatitis-induced injury

Journal

NUTRITION & DIABETES
Volume 3, Issue -, Pages -

Publisher

NATURE PUBLISHING GROUP
DOI: 10.1038/nutd.2013.22

Keywords

Lycium barbarum polysaccharides; non-alcoholic fatty liver disease; fibrosis; oxidative stress; inflammation

Funding

  1. Small Project Funding
  2. University Research Committee
  3. HKU
  4. General Research Fund
  5. University Grant Council
  6. Hong Kong SAR
  7. Azalea Endowment Fund

Ask authors/readers for more resources

Background: Lycium barbarum polysaccharides (LBPs) are antioxidant and neuroprotective derivative from Wolfberry. However, whether LBP has a protective effect in non-alcoholic steatohepatitis (NASH)-induced hepatic injury is still unknown. Objective: We aimed to study the possible hepatoprotective effects and mechanisms of LBP on a diet-induced NASH rat model. Methods and Design: In this study, female rats were fed a high-fat diet to induce NASH with or without an oral 1 mg kg(-1) LBP feeding daily for 8 weeks. After 8 weeks, blood serum and liver samples from each rat were subjected to histological analysis, biochemical and molecular measurements. Results: Compared with control rats, NASH rats showed typical NASH features including an increase in liver injury, lipid content, fibrosis, oxidative stress, inflammation and apoptosis. In contrast, NASH+LBP-co-treated rats showed (1) improved histology and free fatty acid levels; (2) re-balance of lipid metabolism; (3) reduction in profibrogenic factors through the TGF-beta/SMAD pathway; (4) improved oxidative stress through cytochrome P450 2E1-dependent pathway; (5) reduction in hepatic pro-inflammatory mediators and chemokines production; and (6) amelioration of hepatic apoptosis through the p53-dependent intrinsic and extrinsic pathways. The preventive effects of LBP were partly modulated through the PI3K/Akt/FoxO1, LKB1/AMPK, JNK/c-Jun and MEK/ERK pathways and the downregulation of transcription factors in the liver, such as nuclear factor-kappa B and activator protein-1. Conclusion: LBP is a novel hepatoprotective agent against NASH caused by abnormal liver metabolic functions.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available